Please login to the form below

FujiFilm

This page shows the latest FujiFilm news and features for those working in and with pharma, biotech and healthcare.

Bayer takes control of BlueRock stem cell joint venture

The venture unit followed that a few weeks later with a $215m investment in Century Therapeutics, with additional backing for the company coming from Versant and Fujifilm Cellular Dynamics.

Latest news

Pfizer closes on EU approval of lung cancer drug Vizimpro

The two new biosimilars will join products from Amgen, Samsung Bioepis/Biogen, Mylan/Fujifilm Kyowa Kirin, and Novartis’ Sandoz unit in an assault on AbbVie’s market share for the
NHS says Humira biosimilar deal will save £300m

s Cyltezo and Mylan’s Hulio, the latter sublicensed from Japan’s Fujifilm Kyowa Kirin.
First Humira biosimilars reach EU market

Copycat versions of the TNF inhibitor from Amgen, Samsung Bioepis/Biogen, Mylan/Fujifilm Kyowa Kirin, and Novartis’ Sandoz unit are starting to become available in their first EU markets now that ... Imraldi. There is no word yet on the roll-out
Fujifilm expands biopharma development and manufacturing business

Company invests 3.2bn yen in US and UK sites. Fujifilm Corporation is investing 3.2bn yen ($28m) to expand the biopharmaceutical manufacturing and development operations of its contract development and ... More specifically, the new investment will
Novartis to buy French radiopharma specialist AAA for $3.9bn

The first patient was recently treated with the drug in Japan, where it is partnered with Fujifilm RI Pharma.

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Deal Watch March 2016

The sale of the diagnostic imaging business was believed to be hotly contested by Fujifilm and Konica Minolta, with Canon the successful bidder.
Pharma deals in July 2015

Still in Japan, a week later AZ agreed a joint venture with Fujifilm Kyowa Kirin Biologics for the development and commercialisation of a biosimilar version of bevacizumab (Avastin) in phase I ... Fujifilm Kyowa KirinBiologics will transfer the product
Pharma deals in March 2015

The high level of interest in cell therapies generally may have been one reason why Fujifilm acquired Cellular Dynamics for $307m at an eye watering share price premium of 108%. ... Fujifilm expects to achieve significant synergies. Checkpoint inhibitors

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

BIA elects six new board members

The remaining new appointments are Stephen Taylor of Fujifilm Diosynth Biotechnologies; Donna Hackett, director of life sciences consultancy firm KDH BioManagement; and Tim Watts, chief financial officer of Oxford BioMedica.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Working together against COVID-19: Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19: Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?: Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....